[CAS NO. 79125-22-7] Bopindolol fumarate
PRODUCTS SPECIFICATIONS [79125-22-7]
DESCRIPTION [79125-22-7]
Overview
| MDL | - |
|---|---|
| Molecular Weight | 496.55 |
| Molecular Formula | C27H32N2O7 |
| SMILES | CC(N1)=CC2=C1C=CC=C2OCC(OC(C3=CC=CC=C3)=O)CNC(C)(C)C.O=C(O)/C=C/C(O)=O |
Summary
Bopindolol ((±)-Bopindolol) fumarate is an orally active antagonist of β-adrenoceptors (ARs) with partial agonist activity. Bopindolol fumarate is non-selective for β1- and β2-ARs and has low affinity for β3-AR subtype. Bopindolol fumarate has intrinsic sympathomimetic as well as membrane stabilizing actions, inhibits renin secretion, and interacts with 5-HT receptors. Bopindolol fumarate is a proagent of Pindolol ( HY-B0982 ). Bopindolol fumarate can be used for essential and renovascular hypertension research.
IC50 & Target
|
β1 adrenoceptor |
β2 adrenoceptor |
β3 adrenoceptor |
In Vivo
Bopindolol (intravenous injection; 8, 16 and 32 μg/kg) causes a dose-dependent inhibition of isoprenaline-induced tachycardia, and this agent is 4 times more potent than propranolol in anaesthetised dogs
[1]
.
Bopindolol (0.3, 1 and 3 mg/kg; IP; single dosage) produces dose dependent decreases in diastolic blood pressure and in heart rate
[2]
.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| Animal Model: | Male Wistar rats (260-300 g) [2] |
| Dosage: | 0.3, 1 and 3 mg/kg |
| Administration: | IP; single dosage |
| Result: |
Produced dose dependent decreases in diastolic blood pressure, and the decrease of about 8 mmHg at 3 mg/kg.
Decreased the heart rate in a dose-dependent manner. |
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
References
- [1] D W Harron, et al. Bopindolol. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy. Drugs
- [2] H Tanaka, et al. Hypotensive effect of bopindolol in pithed rats. Gen Pharmacol. 1993 Mar;24(2):373-5.
- [3] Y Hosohata, et al. Bopindolol is a slowly dissociating beta 1-adrenoceptor antagonist when compared to other beta-blockers. Biol Pharm Bull. 1995 Aug;18(8):1066-71.
- [4] Nagatomo T, et al. Bopindolol: pharmacological basis and clinical implications. Cardiovasc Drug Rev. 2001 Spring;19(1):9-24.
